Search

Your search keyword '"Almaani, Salem"' showing total 194 results

Search Constraints

Start Over You searched for: Author "Almaani, Salem" Remove constraint Author: "Almaani, Salem"
194 results on '"Almaani, Salem"'

Search Results

1. Growth in children with nephrotic syndrome: a post hoc analysis of the NEPTUNE study

2. Longitudinal analysis of blood pressure and lipids in childhood nephrotic syndrome

3. Systemic Lupus Erythematosus

4. Association of COVID-19 Versus COVID-19 Vaccination With Kidney Function and Disease Activity in Primary Glomerular Disease: A Report of the Cure Glomerulonephropathy Study

5. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

6. Urine and Plasma Complement Ba Levels During Disease Flares in Patients With Antineutrophil Cytoplasmic Autoantibody–Associated Vasculitis

8. Age of Onset and Disease Course in Biopsy-Proven Minimal Change Disease: An Analysis From the Cure Glomerulonephropathy Network

9. Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

10. The Significance of Hematuria in Podocytopathies

11. Pregnancy History and Kidney Disease Progression Among Women Enrolled in Cure Glomerulonephropathy

13. Racial and Ethnic Disparities in Acute Care Utilization Among Patients With Glomerular Disease

14. Rethinking Lupus Nephritis Classification on a Molecular Level.

16. Molecular profiling of kidney compartments from serial biopsies differentiate treatment responders from non-responders in lupus nephritis

20. Persistent Disease Activity in Patients With Long-Standing Glomerular Disease

22. Rationale and design of the Nephrotic Syndrome Study Network (NEPTUNE) Match in glomerular diseases: designing the right trial for the right patient, today

26. Health-related quality of life in glomerular disease

27. CureGN Study Rationale, Design, and Methods: Establishing a Large Prospective Observational Study of Glomerular Disease

28. Kidney disease

29. Contributors

30. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

32. Association of COVID-19 Versus COVID-19 Vaccination With Kidney Function and Disease Activity in Primary Glomerular Disease: A Report of the Cure Glomerulonephropathy Study

33. Rationale and design of the Nephrotic Syndrome Study Network (NEPTUNE) Match in glomerular diseases: designing the right trial for the right patient, today

35. Impact of concurrent glomerulonephritis on outcomes of diffuse alveolar haemorrhage in antineutrophil cytoplasmic antibody-associated vasculitis

37. Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

38. Racial and Ethnic Disparities in Acute Care Utilization Among Patients With Glomerular Disease

40. Age of Onset and Disease Course in Biopsy-Proven Minimal Change Disease: An Analysis From the Cure Glomerulopathy Network

41. Glomerular crescents, IgA-deposits, ANCA, infection – unravelling the diagnostic conundrum

42. Beta-Adrenergic Antagonist Tolerance in Amyloid Cardiomyopathy

45. Validating a Computable Phenotype for Nephrotic Syndrome in Children and Adults Using PCORnet Data

50. Racial-Ethnic Differences in Health-Related Quality of Life among Adults and Children with Glomerular Disease

Catalog

Books, media, physical & digital resources